FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283766650> ?p ?o ?g. }

• W4283766650 abstract "Objective Since 2016, the Chinese government has been regularly implementing the National Reimbursement Drug List Negotiation (NRDLN) to improve the accessibility of drugs. In the second round of NRDLN in July 2017, 18 anticancer drugs were included. This study analyzed the impact of the NRDLN on the accessibility of these 18 anticancer drugs in China. Methods National hospital procurement data were collected from 2015 to 2019. As measurements of drug accessibility, monthly average of drug availability or defined daily dose cost (DDDc) was calculated. Interrupted time series (ITS) analysis was employed to evaluate the impact of NRDLN on drug accessibility. Multilevel growth curve models were estimated for different drug categories, regions or levels of hospitals. Results The overall availability of 18 anticancer drugs increased from about 10.5% in 2015 to slightly over 30% in 2019. The average DDDc dropped from 527.93 CNY in 2015 to 401.87 CNY in 2019, with a reduction of 23.88%. The implementation of NRDLN was associated with higher availability and lower costs for all 18 anticancer drugs. We found an increasing level in monthly drug availability (β 2 = 2.1126), which ascended more sharply after the implementation of NRDLN (β 3 = 0.3656). There was a decreasing level in DDDc before July 2017 (β 2 = −108.7213), together with a significant decline in the slope associated with the implementation of NRDLN (β 3 = −4.8332). Compared to Traditional Chinese Medicines, the availability of Western Medicines was higher and increased at a higher rate (β 3 = 0.4165 vs. 0.1108). Drug availability experienced a larger instant and slope increase in western China compared to other regions, and in secondary hospitals than tertiary hospitals. Nevertheless, regional and hospital-level difference in the effect of NRDLN on DDDc were less evident. Conclusion The implementation of NRDLN improves the availability and reduces the cost of some anticancer drugs in China. It contributes to promoting accessibility of anticancer drugs, as well as relieving regional or hospital-level disparities. However, there are still challenges to benefit more patients sufficiently and equally. It requires more policy efforts and collaborative policy combination." @default.
• W4283766650 created "2022-07-02" @default.
• W4283766650 creator A5013881064 @default.
• W4283766650 creator A5027122519 @default.
• W4283766650 creator A5030161063 @default.
• W4283766650 creator A5040005368 @default.
• W4283766650 creator A5049183561 @default.
• W4283766650 creator A5061887142 @default.
• W4283766650 creator A5064191269 @default.
• W4283766650 creator A5077353246 @default.
• W4283766650 creator A5079642167 @default.
• W4283766650 creator A5083402923 @default.
• W4283766650 creator A5084749638 @default.
• W4283766650 creator A5088169610 @default.
• W4283766650 date "2022-07-01" @default.
• W4283766650 modified "2023-10-14" @default.
• W4283766650 title "Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study" @default.
• W4283766650 cites W1911768300 @default.
• W4283766650 cites W1998754678 @default.
• W4283766650 cites W2110132657 @default.
• W4283766650 cites W2115112857 @default.
• W4283766650 cites W2161170278 @default.
• W4283766650 cites W2483104935 @default.
• W4283766650 cites W2551802175 @default.
• W4283766650 cites W2555117436 @default.
• W4283766650 cites W2559258580 @default.
• W4283766650 cites W2612630315 @default.
• W4283766650 cites W2741088732 @default.
• W4283766650 cites W2782449919 @default.
• W4283766650 cites W2783349575 @default.
• W4283766650 cites W2787553551 @default.
• W4283766650 cites W2808194243 @default.
• W4283766650 cites W2884071619 @default.
• W4283766650 cites W2889646458 @default.
• W4283766650 cites W2890430196 @default.
• W4283766650 cites W2895926023 @default.
• W4283766650 cites W2912312465 @default.
• W4283766650 cites W2941642079 @default.
• W4283766650 cites W2962706009 @default.
• W4283766650 cites W2979284632 @default.
• W4283766650 cites W3000737155 @default.
• W4283766650 cites W3003942896 @default.
• W4283766650 cites W3007690595 @default.
• W4283766650 cites W3181146697 @default.
• W4283766650 cites W3192417164 @default.
• W4283766650 cites W4214669832 @default.
• W4283766650 cites W4247949143 @default.
• W4283766650 cites W4255159504 @default.
• W4283766650 doi "https://doi.org/10.3389/fpubh.2022.921093" @default.
• W4283766650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35844892" @default.
• W4283766650 hasPublicationYear "2022" @default.
• W4283766650 type Work @default.
• W4283766650 citedByCount "4" @default.
• W4283766650 countsByYear W42837666502022 @default.
• W4283766650 countsByYear W42837666502023 @default.
• W4283766650 crossrefType "journal-article" @default.
• W4283766650 hasAuthorship W4283766650A5013881064 @default.
• W4283766650 hasAuthorship W4283766650A5027122519 @default.
• W4283766650 hasAuthorship W4283766650A5030161063 @default.
• W4283766650 hasAuthorship W4283766650A5040005368 @default.
• W4283766650 hasAuthorship W4283766650A5049183561 @default.
• W4283766650 hasAuthorship W4283766650A5061887142 @default.
• W4283766650 hasAuthorship W4283766650A5064191269 @default.
• W4283766650 hasAuthorship W4283766650A5077353246 @default.
• W4283766650 hasAuthorship W4283766650A5079642167 @default.
• W4283766650 hasAuthorship W4283766650A5083402923 @default.
• W4283766650 hasAuthorship W4283766650A5084749638 @default.
• W4283766650 hasAuthorship W4283766650A5088169610 @default.
• W4283766650 hasBestOaLocation W42837666501 @default.
• W4283766650 hasConcept C118552586 @default.
• W4283766650 hasConcept C138885662 @default.
• W4283766650 hasConcept C160735492 @default.
• W4283766650 hasConcept C162324750 @default.
• W4283766650 hasConcept C166957645 @default.
• W4283766650 hasConcept C191935318 @default.
• W4283766650 hasConcept C205649164 @default.
• W4283766650 hasConcept C27415008 @default.
• W4283766650 hasConcept C2778137410 @default.
• W4283766650 hasConcept C2779703844 @default.
• W4283766650 hasConcept C2780035454 @default.
• W4283766650 hasConcept C2780089965 @default.
• W4283766650 hasConcept C33070731 @default.
• W4283766650 hasConcept C41895202 @default.
• W4283766650 hasConcept C50522688 @default.
• W4283766650 hasConcept C71924100 @default.
• W4283766650 hasConcept C86803240 @default.
• W4283766650 hasConcept C98274493 @default.
• W4283766650 hasConceptScore W4283766650C118552586 @default.
• W4283766650 hasConceptScore W4283766650C138885662 @default.
• W4283766650 hasConceptScore W4283766650C160735492 @default.
• W4283766650 hasConceptScore W4283766650C162324750 @default.
• W4283766650 hasConceptScore W4283766650C166957645 @default.
• W4283766650 hasConceptScore W4283766650C191935318 @default.
• W4283766650 hasConceptScore W4283766650C205649164 @default.
• W4283766650 hasConceptScore W4283766650C27415008 @default.
• W4283766650 hasConceptScore W4283766650C2778137410 @default.
• W4283766650 hasConceptScore W4283766650C2779703844 @default.
• W4283766650 hasConceptScore W4283766650C2780035454 @default.
• W4283766650 hasConceptScore W4283766650C2780089965 @default.
• W4283766650 hasConceptScore W4283766650C33070731 @default.

• next